Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
2.02B
Market cap2.02B
Price-Earnings ratio
-9.39
Price-Earnings ratio-9.39
Dividend yield
Dividend yield
Average volume
929.83K
Average volume929.83K
High today
High today
Low today
Low today
Open price
$28.84
Open price$28.84
Volume
0.00
Volume0.00
52 Week high
$40.22
52 Week high$40.22
52 Week low
$12.72
52 Week low$12.72

Stock Snapshot

With a market cap of 2.02B, Stoke Therapeutics(STOK) trades at $31.67. The stock has a price-to-earnings ratio of -9.39.

During the trading day, Stoke Therapeutics(STOK) stock saw an opening price of $28.84, a peak of —, and a bottom of —.

Trading volume for Stoke Therapeutics(STOK) stock has reached 0, versus its average volume of 929.83K.

The stock's 52-week range extends from a low of $12.72 to a high of $40.22.

The stock's 52-week range extends from a low of $12.72 to a high of $40.22.

STOK News

Benzinga 22h
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter. The company reported quarterly losses of 93 cents per share which mi...

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
TipRanks 2d
Stoke Therapeutics Expands ATM Equity Program for Funding

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 2d
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)

Reports Q2 revenue $9.325M, consensus $5.09M. “We have made significant progress across our business this year, including the rapid enrollment of 162 patients i...

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.